Increased urinary antidiuretic hormone excretion by imipramine

Area of Science:

• Neuroendocrinology
• Pharmacology
• Psychiatry

Background:

• Antidiuretic hormone (ADH) plays a crucial role in fluid balance and has been implicated in mood regulation.
• Imipramine is a tricyclic antidepressant commonly used to treat major depressive disorder.
• Alterations in neuroendocrine function are often observed in patients with depression.

Purpose of the Study:

• To investigate the effect of imipramine treatment on urinary antidiuretic hormone (ADH) excretion profiles.
• To compare ADH excretion levels in patients with depression receiving imipramine versus healthy controls.

Main Methods:

• Urinary ADH levels were measured in seven healthy individuals and ten patients with depression treated with 75 mg of imipramine orally.
• Blood pressure was monitored in both groups to ensure safety and control for potential confounding factors.

Main Results:

• Imipramine-treated patients exhibited significantly higher urinary ADH excretion (10.6 +/- 0.83 mU/hr) compared to healthy control subjects (2.6 +/- 0.35 mU/hr).
• The difference in ADH excretion between the groups was statistically significant (P < 0.01).
• Blood pressure remained within normal ranges for all participants, indicating no adverse hemodynamic effects.

Conclusions:

• Imipramine treatment is associated with increased urinary ADH excretion in patients with depression.
• These findings suggest a potential role for ADH dysregulation in the pathophysiology of depression or as a side effect of imipramine therapy.
• Further research is warranted to elucidate the precise mechanisms underlying this observed association.